Progression free-survival at the primary analysis was significantly longer with afatinib than with erlotinib ( median 24 months [ 95 % CI 19-29 ] vs 19 months [ 19-22 ] ; hazard ratio [ HR ] 082 [ 95 % CI 068-100 ] , p = 00427 ) .